Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01631773 · ClinicalTrials.gov registry record
A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only
A clinical trial, sponsored by University of South Florida.
- Completed
- Registry status
- 26
- Enrollment target
NCT01631773: Completed study, sponsored by University of South Florida.
NCT01631773 is a clinical trial that has completed, run by University of South Florida. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01631773 has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).
Primary Outcome
5 total groups
Interventions
- GENETIC microRNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
What the finished NCT01631773 record still lists
NCT01631773 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which microRNA is the first listed.
NCT01631773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01631773 about?
NCT01631773 is a clinical study titled "A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only". We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).
What is the current status of trial NCT01631773?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2011-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01631773?
The interventions under investigation include: microRNA (GENETIC).
Who is sponsoring clinical trial NCT01631773?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia